ClinicalTrials.gg
CompletedNCT00288379Updated Jan 24, 2011

SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma

A Phase 3 interventional study of formoterol and budesonide/formoterol in Asthma, sponsored by AstraZeneca. Completed at 1 site in Sweden. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
77th of 85
16 · median 100
Started
2004
with 9 others
Phase 3
48 of 86
2 open now
Registered
14th of 86
by date
Lead sponsor
25 of 86
AstraZeneca

Among the 86 studies testing formoterol in Asthma, this one is the 77th largest by enrollment of the 85 interventional ones that give a count, is one of 10 that started in 2004, is one of 48 in phase 3, and was the 14th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose allergen challenge in allergic patients with mild asthma

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • allergen challenge
  • airway responsiveness
  • airway inflammation
  • Symbicort®
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosed history of asthma for at least 6 months
  • Mild and stable asthma, only using β2-agonists as needed for the last 4 weeks.
  • >70% of predicted normal value (post-bronchodilator value).
  • Skin prick test positive to pollen, animal dander or house dust mite.

Exclusion criteria

Exclusion Criteria:

  • Any significant respiratory disease, other than asthma.
  • Upper or lower respiratory tract infection within 4 weeks before inclusion.
  • Use of:

    1. inhaled glucocorticosteroid treatment for the last 8 weeks prior to inclusion or ever used oral treatment for asthma.
    2. inhaled long-acting or oral b2-agonists, anticholinergic bronchodilators, cromones, antihistamines, theophyllines and anti-leukotrienes within 2 weeks of screening.
    3. regular NSAIDs
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
16 participants

Interventions

06

What researchers measure

Primary outcomes

  1. PD20 methacholine (measured as the change using the measurement before and after each treatment period).

Secondary outcomes

  1. eNO (ppb).

  2. Forced Expiratory Volume in one second (FEV1 ) - Induced sputum:

  3. Total and differential blood cell count

  4. Different Biomarkers

  5. Safety endpoints will be incidence of Serious Adverse Events (SAEs)

  6. Discontinuation due to Adverse Events (DAEs).

07

Study locations

1 site
  • Research Site
    Stockholm, Sweden
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a completion of May 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2006
First posted
Feb 8, 2006
Start
Oct 2004
CompletionActual
May 2006
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00288379
Lead sponsor
AstraZeneca
First posted
Feb 8, 2006
Start date
Oct 2004
Completion
May 2006
Last update
Jan 24, 2011

Study contacts

AstraZeneca Symbicort Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Formoterol · Budesonide

Start the discussion